PLOS ONE

Lipoprotein subfraction profiling in the search of new risk markers for myocardial infarction: The HUNT study

Sigri Bakken Sperstad[1,2☯], Julie Caroline Sæther[1,3☯]*, Marie Klevjer[1,3], Guro Fanneløb Giskeødegård[4], Tone Frost Bathen[1], Ragnhild Røsbjørgen[1], Håvard Dalen[1,3,5], Anja Bye[1,3]

1 Department of Circulation and Medical Imaging, NTNU, Trondheim, Norway, 2 Department of Biotechnology and Nanomedicine, SINTEF Industry, Trondheim, Norway, 3 Clinic of Cardiology, St. Olavs University Hospital, Trondheim, Norway, 4 Department of Public Health and Nursing, K.G. Jebsen Center for Genetic Epidemiology, Trondheim, Norway, 5 Department of Medicine, Levanger Hospital, Nord-Trøndelag Hospital Trust, Levanger, Norway

☯ These authors contributed equally to this work.

* julie.c.sather@ntnu.no

Abstract

Background

Traditional biomarkers used to measure risk of myocardial infarction (MI) only explain a modest proportion of the incidence. Lipoprotein subfractions have the potential to improve risk prediction of MI.

Aim

We aimed to identify lipoprotein subfractions that were associated with imminent MI risk.

Methods

We identified apparently healthy participants with a predicted low 10-year risk of MI from The Trøndelag Health Survey 3 (HUNT3) that developed MI within 5 years after inclusion (cases, n = 50) and 100 matched controls. Lipoprotein subfractions were analyzed in serum by nuclear magnetic resonance spectroscopy at time of inclusion in HUNT3. Lipoprotein subfractions were compared between cases and controls in the full population (N = 150), and in subgroups of males (n = 90) and females (n = 60). In addition, a sub analysis was performed in participants that experienced MI within two years and their matched controls (n = 56).

Results

None of the lipoprotein subfractions were significantly associated with future MI when adjusting for multiple testing (p<0.002). At nominal significance level (p<0.05), the concentration of apolipoprotein A1 in the smallest high-density lipoprotein (HDL) subfractions was higher in cases compared to controls. Further, in sub analyses based on sex, male cases had lower lipid concentration within the large HDL subfractions and higher lipid concentration within the small HDL subfractions compared to male controls (p<0.05). No differences

were found in lipoprotein subfractions between female cases and controls. In sub analysis
of individuals suffering from MI within two years, triglycerides in low-density lipoprotein were
higher among cases ($p < 0.05$).

Conclusion

None of the investigated lipoprotein subfractions were associated with future MI after adjust-
ment for multiple testing. However, our findings suggests that HDL subfractions may be of
interest in relation to risk prediction for MI, especially in males. This need to be further inves-
tigated in future studies.

Background

Coronary artery disease (CAD) is the leading cause of mortality and morbidity worldwide.
The number of people at risk will increase due to increasing obesity, diabetes type 2, inactivity,
and ageing, implying that this will continue to be a socioeconomic burden in the years to come
[1, 2].

Coronary atherosclerosis, the formation of lipid-rich plaque in the arterial walls, is the most
prevalent underlying cause of CAD [1]. Known risk factors, including lipid measurements
such as high levels of low-density lipoprotein cholesterol (LDL-C) and low levels of high-den-
sity lipoprotein cholesterol (HDL-C), fail to fully predict the risk of CAD, and several patients
with estimated low risk suffer from myocardial infarction (MI) each year [3, 4]. Thus, there is
a clinical need for new biomarkers that could identify patients with subclinical atherosclerosis
with greater precision than today.

Conventional lipid measurements do not differentiate between size, density, or concentra-
tions and compositions of lipoproteins. On the other hand, lipidomics, a recently developed
research field using high-throughput profiling, can produce comprehensive analysis of cellular
lipids. Lipidomics analyses may therefore provide additional information that is missing in
today's evaluation of cardiovascular disease risk [3, 5]. It is well known that the risk of CAD
and the lipoprotein profile is sex specific, and a refined lipid analyses may help identify sex spe-
cific markers that are necessary to improve risk prediction of CAD. In the present study, we
aim to investigate whether lipoprotein subfractions are associated with a 5-year risk of MI in
apparently healthy individuals with predicted low 10-year risk of MI, both in the full popula-
tion and separate for males and females. Furthermore, we aimed to investigate whether lipo-
protein subfractions are associated with 2-year risk of MI.

Materials and methods

Study design and ethics

This study was approved by the Regional Committee for Medical and Health Research Ethics
of central Norway (138187) and The Trøndelag Health Study (HUNT, 2020/18421). All proce-
dures and data handling were performed according to laws and the Declaration of Helsinki,
and all participants gave written informed consent.

Study participants

The Trøndelag Health Survey 3 (HUNT3) is a large population-based health study where
blood samples, clinical measurements, and several questionnaires were collected from 50807

participants between the years 2006–2008 [6]. From this selection, we identified 150 eligible patients based on the following criteria: At time of inclusion in the HUNT3 survey, all participants had to be apparently healthy and between 45–74 years. The participants were considered healthy if they did not have any of the following conditions at inclusion; self-reported CVD (including MI, stroke, angina pectoris, heart failure or other reported heart diseases), chronic kidney disease, diabetes mellitus, body mass index (BMI) > 40 and/or cholesterol-lowering medications. In addition, all participants had to have low risk of acute MI or cerebral stroke within the next 10 years after inclusion in the HUNT3 survey, evaluated by the Norwegian risk model, NORRISK 2, for acute MI and cerebral stroke [7]. From this selection, we identified 50 cases with MI, coded I21 by the International Classification of Diseases 10th revision, experienced within 5 years from inclusion in the HUNT3 survey by using data from the local myocardial infarction registry (Helse Nord-Trøndelag). One hundred controls that matched the cases on age and sex and remained healthy for 10 years after inclusion in the HUNT3 survey, were selected. The controls were considered healthy if they did not have any of the following conditions at The Trøndelag Health Survey 4 (HUNT4); self-reported CVD, chronic kidney disease, diabetes, body mass index (BMI) > 40, and/or use of cholesterol-lowering medication. A flowchart of the inclusion process can be viewed in S1 Fig. From this selection, sub analyses were performed in females (cases = 20, controls = 40), males (cases = 30, controls = 60), and in 2-year MI risk (cases = 19, controls = 38).

Measurements performed by The HUNT study

At the time of inclusion in the HUNT3 survey, weight and height of the participants were measured on a combined scale (Model DS-102, Arctic Heating AS, Nøtterøy, Norway), BMI was calculated as weight divided by height squared (kg/m^2), and blood pressure and resting heart rate were measured by established guidelines in a sitting position[14] (Critikon Dinamap 845XT, GE Medical Systems, Lille Chalfont, Buckinghamshire, United Kingdom).

Blood sampling by The HUNT study

Biochemical analyses were performed on fresh venous blood samples at Levanger Hospital, Norway. Non fasting glucose (mmol/L) was analyzed by Hexokinase/G-G-PDH methodology (reagent kit 3L82-20/3L82-40 Glucose, Abbot, Clinical Chemistry, USA), HDL-cholesterol (mmol/L) was analyzed by Accelerator selective detergent methodology (reagent kit 3K33-20 Ultra HDL, Abbot, Clinical Chemistry, USA), triglycerides (mmol/L) was analyzed by Glycerol Phosphate Oxidase methodology, and LDL-cholesterol was calculated using the Friedewald formula (21). Remaining serum samples were stored at -80˚C in the HUNT biobank. In the present study, 250 μL frozen serum from each participant were used for lipoprotein subfraction analysis.

Nuclear magnetic resonance spectroscopy

Serum samples were analyzed for lipoproteins and lipoprotein subfractions by nuclear magnetic resonance (NMR) spectroscopy at the MR Core Facility at the Norwegian University of Science and Technology in Trondheim, Norway. 120 μL serum was mixed with 120 μL buffer (20% D_2O with 0.075 M Na_2HPO_4, 6 mM NaN_3, 4,6 mM trimethylsilylpropanoic acid, pH 7.4) and transferred to 3-mm NMR tubes. The analyses were performed on Bruker Avance III UltraShield Plus 600 MHz spectrometer (Bruker BioSpin) equipped with a 5mm broad band inverse (BBI) probe. Further procedures were fully automated using a SampleJet with Icon-NMR on Topspin 3.6.2 (Bruker BioSpin). 1D 1H Nuclear Overhauser effect spectroscopy (NOESY) and Carr–Purcell–Meiboom–Gill (CPMG) spectra with water presaturation were

obtained at 310 K using acquisition and processing parameters similar to Dona et al. [8]. The automated Bruker IVDr Lipoprotein Subclass Analysis (B.I.LISA™) method was used to quantify the lipoprotein parameters (23). This method estimated the concentrations of cholesterol, free cholesterol, phospholipids, apolipoprotein A1 (Apo-A1), apolipoprotein A2 (Apo-A2) and apolipoprotein B (Apo-B) in total serum, as well as in each of the lipoproteins (very-low-density lipoprotein (VLDL), intermediate-density lipoprotein (IDL), low-density lipoprotein (LDL), and high-density lipoprotein (HDL)). Each lipoprotein was further divided into subfractions according to their density; VLDL into VLDL-1 to VLDL-5, LDL into LDL-1 to LDL-6, and HDL into HDL-1 to HDL-4, with increasing density (S1 Table). The concentrations of triglycerides, cholesterol, free cholesterol, phospholipids, Apo-A1, Apo-A2 and Apo-B were extracted for each lipoprotein subfraction. Particle numbers for total serum, VLDL, IDL, LDL and in LDL-1-6 were also extracted. In total, the NMR spectroscopy analysis yielded a dataset of 112 variables for each sample. S2 Table and S2 Fig show an overview of all measured variables.

Statistical analyses

Statical analyses were performed by using SPSS Statistics version 27.0 (IBM SPSS, New York, USA) and MATLAB R2017a with PLS_Toolbox 8.2.1 (Eigenvector Research, Inc.). Principal Component Analyses (PCA) were performed on autoscaled lipoprotein concentrations to find possible outliers in the dataset. The Shapiro Wilk test of normality were conducted to check for normally distributed data. None of the lipoprotein subfractions nor other clinical variables were normally distributed, and the Mann Whitney U test were therefore used to compare both clinical characteristics and lipoprotein subfractions between cases and controls. Partial Least Squares Discriminant Analysis (PLS-DA) were applied to compare differences in lipoprotein profile between cases and controls in the full population and separately for males and females. PLS-DA were performed on autoscaled variables and validated by 10-fold cross validation with 20 iterations. Premutation testing with 1000 permutations was performed to determine the significance of the final model. The threshold for nominal significant differences between cases and controls were set to p-value < 0.05. The false discovery rate for the Benjamini-Hochberg test was set to 0.05, resulting in a multiple tested corrected p < 0.002. Continuous data are presented as mean ± standard deviation (SD) and categorical data as counts with percentages.

Results

Characteristics of the study population

Descriptive characteristics of the participants (N = 150) at time of inclusion in the HUNT3 survey are presented in Table 1. None of the registered cardiovascular disease (CVD) risk factors were significantly different between cases and controls. Mean blood pressure, HDL-C and triglycerides were within the recommended range, whereas mean total cholesterol was slightly elevated in both groups. Both groups showed BMI values of 27, equivalent to overweight. Standard laboratory measurements of serum HDL-C and triglycerides from the HUNT3 survey were compared to measurements of HDL-C and triglycerides from NMR spectroscopy to assess internal validity, showing high internal validity (S3 Fig) No outliers were detected in the dataset (S4 Fig).

Lipoprotein subfractions and 5-year MI risk

At time of inclusion in the HUNT3 survey, when all 150 participants were apparently healthy and had a predicted low 10-year risk of MI, none of the lipoprotein subfractions were

Table 1. Characteristics of the participants (N = 150).

Characteristics	Cases (n = 50)	Controls (n = 100)
Sex (female/male)	20/30	40/60
Age (years)	56 ± 6	56 ± 5
Body mass index (kg/m^2)	27.1 ± 3.8	27.0 ± 3.5
Systolic blood pressure (mmHg)	126 ± 14	126 ± 13
Diastolic blood pressure (mmHg)	75 ± 10	74 ± 9
Total cholesterol (mmol/L)	6.1 ± 0.9	5.9 ± 0.7
High-density lipoprotein cholesterol (mmol/L)	1.3 ± 0.4	1.4 ± 0.3
Triglycerides (mmol/L)	1.6 ± 0.7	1.6 ± 0.8
Non-fasting glucose (mmol/L)	5.8 ± 1.1	5.5 ± 0.9
Time since last meal (hours)	3 ± 2	2 ± 2
Medically treated hypertension	7 (16%)	3 (3%)
Smoker, current or previous	33 (66%)	53 (53%)
First degree relative suffering from myocardial infarction before the age of 60 years	12 (32%)	14 (16%)

Data are presented as mean ± standard deviation or number and percentages.

significantly associated with 5-year MI risk after adjustment for multiple testing. However, at nominal significance level ($p < 0.05$), the concentration of Apo-A1 in the smallest HDL subfractions (HDL-4) was higher in cases compared to controls ($p = 0.03$). Fig 1 demonstrates that the elevated concentration of Apo-A1 in HDL-4 in cases is not reflected by measurements of Apo-A1 in the total HDL, potentially masked by the lower levels of Apo-A1 within the larger


Fig 1. Measurements of Apo-A1 in total HDL and in all HDL subfractions (HDL-1 to HDL-4) among cases (n = 50) and controls (n = 100). Boxplots illustrating median (middle line) and mean (+) with upper quartile, lower quartile, minimum value, and maximum value. *Significant at $p < 0.05$. Apo-A1, apolipoprotein A1; HDL, high-density lipoprotein.

HDL subfractions. Extended results, including all lipoprotein subfractions, are listed in
S3 Table.

Subgroup analyses based on sex

From the PLS-DA, the lipid profile of male and females were significantly different (p < 0.001,
S5 Fig), and we therefore performed sub analyses based on sex. Our results showed no signifi-
cant differences in lipoprotein subfractions between female cases and controls (n = 60), but
five HDL subfractions were nominally significantly different between male cases and controls
(n = 90, p < 0.05, Fig 2). Similar to the results in the full population, the Apo-A1 in HDL-4
was found to be elevated in cases compared to controls. In large HDL-subfractions, the con-
centrations of triglycerides and Apo-A2 in HDL-1 and phospholipids and Apo-A2 in HDL-2
were reduced in cases compared to controls (Fig 2). No difference was found between male
cases and controls in concentration of cholesterol and free cholesterol in HDL subfractions.
There seems to be a trend that the HDL subfractions 1–3 are reduced in cases, whereas the
small HDL-4 subfractions are elevated in cases compared to controls (Fig 2). Small and large
HDL particles may therefore possess opposite association with future MI risk. Extended results
for males, including all lipoprotein subfractions, are listed in S4 Table.

Subgroup analysis, lipoprotein subfractions and 2-year MI risk

The cases experienced MI within 5 years despite a predicted low risk of MI at the time of inclu-
sion in the HUNT3 survey. Participants that experienced MI within 2 years are of particular
interest as these are assumed to have a more pronounced risk profile. Therefore, a subgroup
analysis was performed on participants that experienced MI within 2 years (N = 19) and their
matched controls (n = 38). None of the lipoprotein subfractions were significantly associated
with 2-year risk of MI when adjusting for multiple testing. However, cases had 20% higher
concentration of triglycerides in total LDL (LDTG) compared to controls at nominal signifi-
cance level (p < 0.05). Extended results, including all lipoprotein subfractions, are listed in
S5 Table.

Discussion

In the present study, we addressed a clinically important group of individuals that were mis-
takenly classified as low-risk individuals when they should have been classified as high-risk
individuals by the risk prediction model NORRISK 2. Biomarkers that can identify these indi-
viduals may add value to the current risk prediction models, which would be of great clinical
and socioeconomic importance. Thus, we quantified a large number of lipoprotein subfrac-
tions in serum samples from 150 apparently healthy individuals with a predicted low 10-year
risk of MI at the time of inclusion in the HUNT3 survey. The selected cases (n = 50) experi-
enced MI within 5 years after the blood sampling at the time of inclusion in The HUNT3 Sur-
vey, and the matched controls (n = 100) remained healthy during the 10-year observation
period. We investigated the association between lipoprotein subfractions and a 5-year risk of
MI. None of the analyzed lipoprotein subfractions were significantly associated with future MI
after adjusting for multiple testing, but some passed the nominal significance threshold.

   Quantification of circulating Apo-A1 is occasionally performed in the clinical setting, but it
is currently not a part of standard CVD risk evaluation [9]. In the present study, there were
indications of increased concentrations of Apo-A1 in the smallest HDL particles (HDL-4) in
cases compared to controls, despite the presumed cardioprotective role of Apo-A1 and HDL
[10]. There were no differences in the concentration of Apo-A1 in total HDL between the
groups. This is in line with the assumption that not all HDL subfractions have atheroprotective

Fig 2. Measurement of Apo-A1, Apo-A2, phospholipids, free cholesterol, cholesterol, and triglycerides in all HDL subfractions (HDL-1 to HDL-4) among male cases (n = 30) and male controls (n = 60). Boxplots illustrating median (middle line) and mean (+) with upper quartile, lower quartile, minimum value, and maximum value. *Significant at $p < 0.05$. Apo-A1, apolipoprotein A1; Apo-A2, apolipoprotein A2; HDL, high-density lipoprotein.

properties [11, 12]. Our study suggests that Apo-A1 in HDL-4 may have a concealed proatherogenic effect and that elevated Apo-A1 concentrations in the smallest HDL subfractions may not be an advantage for cardiovascular health. Apo-A1 in HDL-4 might be a potential biomarker of MI risk, but future investigations involving larger studies are needed to verify this assumption.

Results from the multivariate analysis, PLS-DA, showed a significant difference in lipidomic profile of males and females. Previous studies have also demonstrated sex-specific differences in lipidomic risk profile and it is generally known that CVD risk differ between sexes [13]. In sex-specific sub analyses, none of the lipoprotein subfractions were significantly

associated with MI after adjustment for multiple testing, but some passed the nominal significance threshold ($p < 0.05$). This must be taken into consideration when interpreting our results. In males, five lipoprotein subfractions were different between cases and controls at nominal significance threshold. This included elevated concentration of Apo-A1 in HDL-4, reduced concentration of triglycerides and Apo-A2 in HDL-1, and reduced concentration of phospholipids and Apo-A2 in HDL-2 among the cases. These findings indicate that elevated lipid concentration within the small HDL particles as well as reduced lipid concentration within the large HDL particles increases the risk of MI. This is in line with previous studies, suggesting that the size of the HDL particles is of importance in CVD risk prediction, and that large particles may have antiatherogenic properties, whereas small particles may have atherogenic properties [14–16].

Previous studies show that large HDL subfractions are negatively associated with CVD risk, possibly due to the assumed atheroprotective effect of large HDL particles and/or due to the low amount of large HDL particles [10, 16, 17]. It is also generally accepted that cholesterol concentration within the different groups of lipoproteins is associated with CVD risk [18]. However, the associations between CVD risk and the concentration of other lipids within lipoprotein subfractions, including phospholipid, free cholesterol, and Apo-A2, are less studied. Previous studies have debated whether Apo-A2 is an anti- or proatherogenic protein, emphasizing that its role in lipoprotein metabolism is still unknown [19]. Phospholipids and free cholesterol are believed to influence the anti-oxidative properties of HDL, but their mechanisms are unidentified [18]. A previous study investigated the concentration of triglyceride and cholesterol within HDL subfractions and its relation to MI risk by using NMR spectroscopy [17]. They found that triglycerides in all HDL subfractions were positively associated with MI risk, and that cholesterol concentration in medium and large HDL particles were inversely associated to MI risk. This is contrary to our findings, as we found a negative association between triglycerides in large HDL-1 and HDL-2 and risk of MI, and no association between cholesterol in HDL subfractions and risk of MI. Although, it has previously been suggested that high levels cholesterol in large HDL particles are decreases risk of CVD and that high levels of cholesterol in the small HDL particles increases risk [11, 20].

In the sub analyses of apparently healthy cases with a predicted low 10-year risk of MI that experienced MI within 2 years, none of the quantified lipoprotein subfractions were significantly different between cases and controls at time of inclusion in the HUNT3 survey. However, at nominally significance threshold ($p < 0.05$), the concentration of triglycerides in LDL were elevated in cases compared to controls. This is in line with several studies showing a positive association between LDL triglycerides and incident of CVD [21, 22]. It is suggested that this association is independent of LDL cholesterol levels [22]. Triglyceride concentration in blood has also been suggested as a causal risk factor for CVD [23, 24], and LDL triglycerides has previously shown to improve risk prediction of cardiovascular mortality [25]. In the present study, the total concentration of triglycerides in blood were not different between cases and controls, strengthening the relevance of measuring triglycerides of LDL in CVD risk assessment instead of total triglycerides.

To minimize the limitations that comes with a small number of cases available, we included two controls per included case. Still, no significant differences in lipoprotein subfractions between cases and controls were found after adjustment for multiple testing by the false discovery rate approach. This might be explained by the relatively small study population compared with the large number of lipoprotein subfractions measured by NMR spectroscopy. It is suggested that multiple testing is too conservative for lipidomic analyses (39), and a standardized approach are needed to address this issue. Furthermore, to be able to implement lipoprotein subfraction into future clinical risk evaluation, a standardized methods for lipoprotein

subfraction analysis is required. None of the participants reported use of cholesterol-lowering medication at the time of blood sampling in the HUNT3 survey through self-reported information in the HUNT4 survey, including questions about current use of cholesterol-lowering medications (yes/no) and first prescription of the medication (age). All controls reported no use of the cholesterol-lowering medication throughout the 10-year observation period, and cases reported to have started medication subsequently after the event of MI. However, this is self-reported information and should have been verified by the Norwegian Prescription Database. Another limitation in our study is that we included six cases with MI coded as I21.9 by the International Classification of Diseases 10th revision. The underlying cause of MI is unspecified in these cases, and we can therefore not be certain that MI is caused by athero-thrombosis. This may have influenced our results.

Conclusion

In the present study, none of the analyzed lipoprotein subfractions were significantly associated with future MI in apparently healthy individuals with a predicted low 10-year risk of MI after adjusting for multiple testing, but some passed the nominal significance threshold. Hence, there were indications that elevated concentration of Apo-A1 in the small HDL-4 subfractions were associated with a 5-year risk of MI, and that elevated concentration of triglycerides in LDL were associated with a 2-year risk of MI. In sub analyses on sex, HDL subfractions were found as potential sex-specific risk markers of MI in males. Compared to male controls, there were indications that male cases had elevated concentration of Apo-A1 in the small HDL-4 subfraction, and reduced levels of triglycerides, Apo-A2, and phospholipids within the large HDL subfractions (HDL-1 and HDL-2). The present study therefore suggests that lipoprotein subfractions may provide valuable information about MI risk. However, the statistical strength of this study is limited by the small study population. Larger studies are therefore needed to validate our findings and to assess the clinical relevance of lipoprotein subfractions in risk prediction of MI.

Supporting information

S1 Fig. Flowchart of the inclusion process.
(TIF)

S2 Fig. Visual overview of all variables measured by nuclear magnetic resonance spectroscopy.
(TIF)

S3 Fig. Validation of nuclear magnetic resonance spectroscopy analysis data.
(TIF)

S4 Fig. Principal component analyses plot.
(TIF)

S5 Fig. Partial least squares discriminant analysis plots retrieved from nuclear magnetic resonance spectroscopy data.
(TIF)

S1 Table. Density ranges of lipoproteins and lipoprotein subfractions.
(DOCX)

S2 Table. Table overview of all variables measured by nuclear magnetic resonance spectroscopy.
(DOCX)

S3 Table. Comparison of lipid variables between cases and controls (N = 150).
(DOCX)

S4 Table. Comparison of lipid variables levels between male cases and male controls (n = 90).
(DOCX)

S5 Table. Comparison of lipid variables between cases and controls in a 2-year observation period (n = 57).
(DOCX)

Acknowledgments

Author Contributions

Conceptualization: Håvard Dalen, Anja Bye.

Formal analysis: Sigri Bakken Sperstad, Julie Caroline Sæther, Marie Klevjer, Guro Fanneløb Giskeødegård.

Funding acquisition: Anja Bye.

Investigation: Sigri Bakken Sperstad.

Methodology: Guro Fanneløb Giskeødegård, Tone Frost Bathen, Ragnhild Røsbjørgen, Håvard Dalen, Anja Bye.

Project administration: Sigri Bakken Sperstad, Anja Bye.

Resources: Tone Frost Bathen, Ragnhild Røsbjørgen.

Supervision: Anja Bye.

Visualization: Julie Caroline Sæther, Marie Klevjer, Guro Fanneløb Giskeødegård.

Writing – original draft: Sigri Bakken Sperstad, Julie Caroline Sæther, Anja Bye.

Writing – review & editing: Sigri Bakken Sperstad, Julie Caroline Sæther, Marie Klevjer, Guro Fanneløb Giskeødegård, Tone Frost Bathen, Ragnhild Røsbjørgen, Håvard Dalen, Anja Bye.

References

1. Timmis A, Townsend N, Gale CP, Torbica A, Lettino M, Petersen SE, et al. European Society of Cardiology: Cardiovascular Disease Statistics 2019. Eur Heart J. 2020; 41: 12–85. https://doi.org/10.1093/eurheartj/ehz859 PMID: 31820000

2. Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019; 74: 1376–1414. https://doi.org/10.1016/j.jacc.2019.03.009 PMID: 30894319

3. Hoefer IE, Steffens S, Ala-Korpela M, Bäck M, Badimon L, Bochaton-Piallat ML, et al. Novel methodologies for biomarker discovery in atherosclerosis. Eur Heart J. 2015; 36: 2635–42. https://doi.org/10.1093/eurheartj/ehv236 PMID: 26049157

4. Leipsic J, Taylor CM, Grunau G, Heilbron BG, Mancini GB, Achenbach S, et al. Cardiovascular risk among stable individuals suspected of having coronary artery disease with no modifiable risk factors: results from an international multicenter study of 5262 patients. Radiology. 2013; 267: 718–26. https://doi.org/10.1148/radiol.13121669 PMID: 23424261

5. Meikle PJ, Wong G, Barlow CK, Kingwell BA. Lipidomics: potential role in risk prediction and therapeutic monitoring for diabetes and cardiovascular disease. Pharmacol Ther. 2014; 143: 12–23. https://doi.org/10.1016/j.pharmthera.2014.02.001 PMID: 24509229

6. Krokstad S, Langhammer A, Hveem K, Holmen TL, Midthjell K, Stene TR, et al. Cohort Profile: the HUNT Study, Norway. Int J Epidemiol. 2013; 42: 968–77. https://doi.org/10.1093/ije/dys095 PMID: 22879362

7. Selmer R, Igland J, Ariansen I, Tverdal A, Njolstad I, Furu K, et al. NORRISK 2: A Norwegian risk model for acute cerebral stroke and myocardial infarction. Eur J Prev Cardiol. 2017; 24: 773–782. https://doi.org/10.1177/2047487317693949 PMID: 28206819

8. Dona AC, Jiménez B, Schäfer H, Humpfer E, Spraul M, Lewis MR, et al. Precision high-throughput proton NMR spectroscopy of human urine, serum, and plasma for large-scale metabolic phenotyping. Anal Chem. 2014; 86: 9887–94. https://doi.org/10.1021/ac5025039 PMID: 25180432

9. Helsedirektoratet. Nasjonal faglig rettningslinje for forebygging av hjerte- og karsykdom. 3 May 2018.

10. Sacks FM, Jensen MK. From High-Density Lipoprotein Cholesterol to Measurements of Function: Prospects for the Development of Tests for High-Density Lipoprotein Functionality in Cardiovascular Disease. Arter Thromb Vasc Biol. 2018; 38: 487–499. https://doi.org/10.1161/ATVBAHA.117.307025 PMID: 29371248

11. Xu RX, Li S, Li XL, Zhang Y, Guo YL, Zhu CG, et al. High-density lipoprotein subfractions in relation with the severity of coronary artery disease: A Gensini score assessment. J Clin Lipidol. 2015; 9: 26–34. https://doi.org/10.1016/j.jacl.2014.11.003 PMID: 25670357

12. Zeljkovic A, Vekic J, Spasojevic-Kalimanovska V, Jelic-Ivanovic Z, Bogavac-Stanojevic N, Gulan B, et al. LDL and HDL subclasses in acute ischemic stroke: prediction of risk and short-term mortality. Atherosclerosis. 2010; 210: 548–54. https://doi.org/10.1016/j.atherosclerosis.2009.11.040 PMID: 20022325

13. Freedman DS, Otvos JD, Jeyarajah EJ, Shalaurova I, Cupples LA, Parise H, et al. Sex and age differences in lipoprotein subclasses measured by nuclear magnetic resonance spectroscopy: the Framingham Study. Clin Chem. 2004; 50: 1189–200. https://doi.org/10.1373/clinchem.2004.032763 PMID: 15107310

14. Wurtz P, Raiko JR, Magnussen CG, Soininen P, Kangas AJ, Tynkkynen T, et al. High-throughput quantification of circulating metabolites improves prediction of subclinical atherosclerosis. Eur Heart J. 2012; 33: 2307–16. https://doi.org/10.1093/eurheartj/ehs020 PMID: 22450427

15. El Harchaoui K, Arsenault BJ, Franssen R, Després JP, Hovingh GK, Stroes ES, et al. High-density lipoprotein particle size and concentration and coronary risk. Ann Intern Med. 2009; 150: 84–93. https://doi.org/10.7326/0003-4819-150-2-200901200-00006 PMID: 19153411

16. Mora S, Otvos JD, Rifai N, Rosenson RS, Buring JE, Ridker PM. Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. Circulation. 2009; 119: 931–9. https://doi.org/10.1161/CIRCULATIONAHA.108.816181 PMID: 19204302

17. Holmes MV, Millwood IY, Kartsonaki C, Hill MR, Bennett DA, Boxall R, et al. Lipids, Lipoproteins, and Metabolites and Risk of Myocardial Infarction and Stroke. J Am Coll Cardiol. 2018; 71: 620–632. https://doi.org/10.1016/j.jacc.2017.12.006 PMID: 29420958

18. Soppert J, Lehrke M, Marx N, Jankowski J, Noels H. Lipoproteins and lipids in cardiovascular disease: from mechanistic insights to therapeutic targeting. Adv Drug Deliv Rev. 2020. https://doi.org/10.1016/j.addr.2020.07.019 PMID: 32730849

19. Remaley AT. Apolipoprotein A-II: still second fiddle in high-density lipoprotein metabolism? Arter Thromb Vasc Biol. 2013; 33: 166–7. https://doi.org/10.1161/ATVBAHA.112.300921 PMID: 23325471

20. Martin SS, Khokhar AA, May HT, Kulkarni KR, Blaha MJ, Joshi PH, et al. HDL cholesterol subclasses, myocardial infarction, and mortality in secondary prevention: the Lipoprotein Investigators Collaborative. Eur Heart J. 2015; 36: 22–30. https://doi.org/10.1093/eurheartj/ehu264 PMID: 24980493

21. Saeed A, Feofanova EV, Yu B, Sun W, Virani SS, Nambi V, et al. Remnant-Like Particle Cholesterol, Low-Density Lipoprotein Triglycerides, and Incident Cardiovascular Disease. J Am Coll Cardiol. 2018; 72: 156–169. https://doi.org/10.1016/j.jacc.2018.04.050 PMID: 29976289

22. März W, Scharnagl H, Winkler K, Tiran A, Nauck M, Boehm BO, et al. Low-density lipoprotein triglycerides associated with low-grade systemic inflammation, adhesion molecules, and angiographic coronary artery disease: the Ludwigshafen Risk and Cardiovascular Health study. Circulation. 2004; 110: 3068–74. https://doi.org/10.1161/01.CIR.0000146898.06923.80 PMID: 15505088

23. Tada H, Nohara A, Kawashiri MA. Serum Triglycerides and Atherosclerotic Cardiovascular Disease: Insights from Clinical and Genetic Studies. Nutrients. 2018; 10. https://doi.org/10.3390/nu10111789 PMID: 30453617

24. Nordestgaard BG. Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease: New Insights From Epidemiology, Genetics, and Biology. Circ Res. 2016; 118: 547–63. https://doi.org/10.1161/CIRCRESAHA.115.306249 PMID: 26892957

25. Silbernagel G, Scharnagl H, Kleber ME, Delgado G, Stojakovic T, Laaksonen R, et al. LDL triglycerides, hepatic lipase activity, and coronary artery disease: An epidemiologic and Mendelian randomization study. Atherosclerosis. 2019; 282: 37–44. https://doi.org/10.1016/j.atherosclerosis.2018.12.024 PMID: 30685440